Next Big Sales Deal Our ongoing mission is to help the global community curb the spread of COVID-19 by delivering the best tests in the market," said Felipe Peixoto, chief executive officer of VS Health. "This approval from the European Union now allows us to expand our sales and distribution reach of our Safetest suite of tests throughout the EU," said Mr. Peixoto. Mr. Peixoto continued, "The company will immediately look for manufacturing capabilities in the EU to meet the strong demand."
The antibody data provided by VS Health's Safetest COVID-19 IgM/IgG ELISA test kit cover both immunoglobulins type M (IgM) and G (IgG). When IgM antibodies are present, they can indicate that a patient has an active or recent infection with SARS-CoV-2. When IgG antibodies are present, it indicates past infection and exposure. The company has successfully completed the CE marking which indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. It is required for products manufactured anywhere in the world which are then marketed in the EU.
According to EU recommendations, timely and accurate COVID-19 laboratory testing is an essential part of the management of COVID-19 for slowing down the pandemic, supporting decisions on infection control strategies and patient management at health care facilities, and detecting asymptomatic cases that could spread the virus further if not isolated.
"Based on our outreach and discussions, the demand for this critical test from distributors around the world is very high," said Mr. Peixoto. Mr. Peixoto continued: "VS Health is poised to meet the growing need from countries focused on detection and reducing the potential curve with the second wave this fall. We are confident that our exclusive suite and capabilities of our products will meet the increasing EU demand during this pandemic," said Mr. Peixoto.
ELISA Safetest COVID-19 antibody test results are crucial for developing a clear understanding of the immunity thresholds and characteristics of infected individuals. High sensitivity antibody tests provide detailed profiles of populations and individuals. This information helps to accelerate the development of vaccines and provides crucial insight into natural immunity and potential thresholds if they exist. This information will get people back to work, school and normalcy faster and safer.
"We are poised to meet the extensive distribution demands these approvals provide us in the EU, Brazil, the USA and other countries as we rapidly ramp-up our key relationships and supply channels," said Shafin Diamond Tejani, CEO of Victory Square. "The exclusive test has demonstrated excellent reliability through valid data, and we are ready and able to meet the increasing demand globally for our quick, cost-effective and reliable Safetest products to contribute to the global fight against the pandemic."
The company is currently engaging various industries including but not limited to retail, hospitality, pharmaceutical, correctional facilities, casinos, sports, border services, education, transportation, military, government and more.